CLTA-4 blockade in vivo promotes the generation of short-lived effector CD8+ T cells and a more persistent central memory CD4+ T cell response

Journal of Medical Primatology

Volumn 37, Issue SUPPL. 2, 2008, Pages 62-68

  Hokey, David A ^a   Yan, Jian ^a   Hirao, Lauren A ^a   Dai, Anlan ^a   Boyer, Jean D ^a   Jure Kunkel, Maria N ^b   Weiner, David B ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HIV; Ipilimumab; SIV; Vaccine

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAG PROTEIN; IPILIMUMAB; POL PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONFERENCE PAPER; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG PROTEIN BINDING; DRUG RESPONSE; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOREACTIVITY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MACACA; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; MACACA FASCICULARIS; MALE; MODELS, IMMUNOLOGICAL; VACCINES, DNA;

MACACA; MACACA FASCICULARIS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 59149085966     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2008.00324.x     Document Type: Conference Paper

References (32)

1. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72.
2. Amara RR, Ibegbu C, Villinger F, Montefiori DC, Sharma S, Nigam P, Xu Y, McClure HM, Robinson HL: Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. Virology 2005; 343:246-55.
3. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53.
4. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336-47.
5. Croft M: Co-stimulatory members of thK TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609-20.
6. Dranoff G: UTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005; 23:662-4.
7. Frauwirth KA, Thompson CB: Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002; 109:295-9.
8. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005; 23:515-48.
9. Hokey DA, Johnson FB, Smith J, Weber JL, Yan J, Hirao L, Boyer JD, Lewis MG, Makedonas G, Betts MR, Weiner DB: Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol 2008; 38:1435-45.
10. Hokey DA, Weber JL, Yan J, Hirao LA, Dai A, Jure-Kunkel MN, Boyer JD, Weiner DB: CTLA-4 blockade enhances vaccine-specific proliferation and suppressed PD-1 expression in macaques. submitted for publication.
11. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-8.
12. Jankovic V, Messaoudi I, Nikolich-Zugich J: Phenotypic and functional T-cell aging in rhesus macaques (Macaca mulatta): Differential behavior of CD4 and CD8 subsets. Blood 2003; 102:3244-51.
13. Kapadia D, Aong L: CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 2005; 23:8926-8.
14. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-54.
15. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96:15074-9.
16. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94:8099-103.
17. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6.
18. Liu B, Podack ER, Allison JP, Malek TR: Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 1996; 156:1117-25.
19. Maker AV, Attia P, Rosenberg SA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175:7746-54.
20. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98:14565-70.
21. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7:445-80.
22. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 1996; 8:773-80.
23. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, Wang Y, Walunas T, Bluestone J, Listman J, Finn PW: Regulation of CTLA-4 expression during T cell activation. J Immunol 1996; 156:4154-9.
24. Phan GQ, Weber JS, Sondak VK: CTLA-4 Blockade with monoclonal antibodies in patients with metastatic cancer: Surgical issues. Ann Surg Oncol 2008 [epub ahead of print].
25. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-7.
26. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, Axthelm MK, Picker LJ: Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168:29-43.
27. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS: Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150:771-81.
28. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-50.
29. + lymphocytes. Science 1999; 283:857-60.
30. Teft WA, Kirchhof MG, Madrenas J: A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24:65-97.
31. Yan J, Hokey DA, Morrow MP, Corbitt N, Harris K, Harris D, Weiner DB: Novel SIVmac DNA vaccines encoding Env, Pol, and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine 2008; in press.
32. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T: Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57:4036-41.